SLC5A2 and hydrops fetalis: The risks of total CV death or HHF were significantly lower in the SGLT2-inhibitor group than the placebo (RR 0.79, 95% CI 0.74–0.84, P < .01, I2 = 31%), and the risk reductions were consistently significant, irrespective of patients with or without HF (Fig. 1).